Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 15:367:426-433.
doi: 10.1016/j.jad.2024.08.237. Epub 2024 Sep 2.

Depressive symptoms over the final menstrual period: Study of Women's Health Across the Nation (SWAN)

Nancy E Avis  1 , Alicia Colvin  2 , Yuqing Chen  2 , Hadine Joffe  3 , Howard M Kravitz  4
Affiliations

Depressive symptoms over the final menstrual period: Study of Women's Health Across the Nation (SWAN)

Nancy E Avis et al. J Affect Disord. .

Abstract

Background: Women may be vulnerable to elevated depressive symptoms during the menopause transition (MT). Studies generally have not considered premenopausal depressive symptom history or examined symptoms in relation to the final menstrual period (FMP).

Objective: To identify specific time points in relation to the FMP when depressive symptoms increase or decrease.

Methods: Participants were 1582 multiracial/ethnic women from the longitudinal Study of Women's Health Across the Nation (SWAN). Biological, psychosocial, and depressive symptom data were collected approximately annually. Depressive symptoms were measured by the Center for Epidemiological Studies-Depression (CESD) scale.

Results: Women with high baseline depressive symptoms (CES-D ≥ 16) declined in symptoms (M = -1.04/yr., 95 % CI = -1.58, -0.50) until 4 years before the FMP, followed by a smaller decrease (M = -0.50/yr., 95 % CI = -0.72, -0.28) until 18 months after the FMP. Depressive symptoms increased (M = 0.21/yr., 95 % CI = 0.11, 0.30) in those with low baseline symptoms until 1 year before the FMP, and decreased (M = -0.06/yr., 95 % CI = -0.11, -0.008) going forward. Greater social support, higher levels of follicle stimulating hormone and estradiol, and less sleep disturbance contributed to greater decline in depressive symptoms among those with high baseline depressive symptoms. Anxiety, experiencing stressful life events, lower body mass index, and poor role-physical function contributed to an increase in depressive symptoms among those with low baseline symptoms.

Limitations: Excluded women had higher baseline CES-D scores. Lacked pre-MT depression for pre/early perimenopausal women at baseline.

Conclusion: Accounting for baseline depressive symptom level and focusing on the FMP more precisely characterize depressive symptom change over the MT.

Keywords: (3–6): Depressive symptoms; Final menstrual period; Menopause.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Dr. Joffe is a consultant/advisory board member for Bayer, Merck, and Hello Therapeutics, and has grant/research support from Merck, Sage, and Pfizer.

References

    1. Alblooshi S, Taylor M, Gill N 2023. Does menopause elevate the risk for developing depression and anxiety? Results from a systematic review. Australasian Psychiatry 31(2):165–173. doi: 10.1177/10398562231165439. - DOI - PMC - PubMed
    1. Avis NE, Brambilla D, McKinlay SM, & Vass K (1994). A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women’s Health Study. Ann Epidemiol, 4(3):214–20. doi: 10.1016/1047-2797(94)90099-x. - DOI - PubMed
    1. Avis NE, Colvin A, Bromberger JT, Hess R, Matthews KA, Ory M, & Schocken M (2009). Change in health-related quality of life over the menopausal transition in a multiethnic cohort of middle-aged women: Study of Women’s Health Across the Nation. Menopause, 16(5), 860–869. doi:10.1097/gme.0b013e3181a3cdaf - DOI - PMC - PubMed
    1. Barry MJ, Nicholson WK, Silverstein M, Chelmow D, Coker TR, Davidson KW, Davis EM, Donahue KE, Jaén CR, Li L, Ogedegbe G, Pbert L, Rao G, Ruiz JM, Stevermer JJ, Tsevat J, Underwood SM, Wong JB, 2023. Screening for Depression and Suicide Risk in Adults: US Preventive Services Task Force Recommendation Statement. JAMA, 329, 2057–2067. 10.1001/jama.2023.9297. - DOI - PubMed
    1. Bernstein DP, Stein JA, Newcomb MD, Walker E, Pogge D, Ahluvalia T, Stokes J, Handelsman L, Medrano M, Desmond D, Zule W, 2003. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse & Neglect, 27, 169–190. 10.1016/s0145-2134(02)00541-0. - DOI - PubMed

LinkOut - more resources